Skip to main content

Table 2 Results of subgroup analysis of pooled hazard ratios of OS of patients with different SII

From: Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Stratified analysis

No. of studies

Pooled HR (95% CI)

P‐value

Heterogeneity

I2 (%)

PQ

Cancer type

RCC

7

2.73 (1.28, 5.81)

0.009

99

< 0.001

PC

3

2.29 (1.44, 3.63)

< 0.001

46

0.160

BC

2

3.01 (1.35, 6.68)

0.007

0

0.870

Unclear

2

1.92 (1.46, 2.54)

< 0.001

0

0.660

Urothelial cancer

4

2.03 (1.55, 2.63)

< 0.001

0

0.730

Non urothelial cancer

10

2.67 (1.46, 4.88)

0.001

98

< 0.001

Study type

Prospective

1

2.99 (2.07, 4.32)

< 0.001

NA

NA

Retrospective

13

2.55 (1.53, 4.27)

< 0.001

97

< 0.001

Treatment

     

Surgery

5

1.70 (1.04, 2.79)

0.030

76

0.002

Non surgery

7

2.16 (1.74, 2.68)

< 0.001

52

0.050

Mix

2

6.67 (1.40, 31.84)

0.020

98

< 0.001

Cut-off value

 0–500

2

9.05 (2.99, 27.41)

< 0.001

82

0.020

 501–1000

9

1.84 (1.30, 2.59)

< 0.001

90

< 0.001

 >1000

2

3.23 (2.38, 4.39)

< 0.001

0

0.450

Analysis

 Multivariate

10

2.06 (1.44, 2.94)

< 0.001

9.1

< 0.001

 Univariate

1

2.36 (1.78, 3.13)

< 0.001

NA

NA

  1. CI: confidence interval; HR: hazard ratio; OS: overall survival; SII: systemic immune‐inflammation index